Surgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million

Core Viewpoint - Irenic Capital Management has significantly reduced its stake in Surgery Partners, indicating a shift in investment strategy despite the company's operational growth and revenue increase [2][10]. Company Overview - Surgery Partners operates a national network of surgical centers, focusing on outpatient procedures across various medical specialties, including gastroenterology, orthopedics, and ophthalmology [6][9]. - The company reported a total revenue of $3.29 billion and a net income of -$171.40 million for the trailing twelve months (TTM) [4]. - As of February 17, 2026, the market capitalization of Surgery Partners was $2.02 billion, with shares priced at $15.60, reflecting a 39.7% decline over the past year [4][8]. Financial Performance - In the third quarter, Surgery Partners experienced a revenue increase of 6.6% to $821.5 million, with same facility revenues up 6.3% and Adjusted EBITDA rising 6.1% to $136.4 million [11]. - The company anticipates full-year revenue guidance of up to $3.30 billion and Adjusted EBITDA of as much as $540 million [11]. Investment Implications - The recent sale by Irenic Capital Management reduced its position in Surgery Partners to just 0.09% of its $1.49 billion U.S. equity assets under management, indicating a re-prioritization of investment focus [8][10]. - The company's net debt to EBITDA ratio is approximately 4.2x under its credit agreement, which raises concerns in a higher interest rate environment [12]. - For long-term investors, the balance sheet discipline is crucial, as the outpatient model has structural advantages, but high leverage could lead to increased volatility [13].